Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics

Alkermes plc - Ordinary Shares (ALKS): $32.18

0.38 (-1.17%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

A

Add ALKS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#14 of 356

in industry

ALKS Price/Volume Stats

Current price $32.18 52-week high $33.71
Prev. close $32.56 52-week low $22.01
Day low $31.83 Volume 3,746,800
Day high $32.88 Avg. volume 1,699,964
50-day MA $27.81 Dividend yield N/A
200-day MA $28.39 Market Cap 5.37B

ALKS Stock Price Chart Interactive Chart >

ALKS POWR Grades

  • ALKS scores best on the Value dimension, with a Value rank ahead of 98.46% of US stocks.
  • ALKS's strongest trending metric is Stability; it's been moving down over the last 175 days.
  • ALKS ranks lowest in Stability; there it ranks in the 11th percentile.

ALKS Stock Summary

  • ALKS's went public 32.49 years ago, making it older than 83.94% of listed US stocks we're tracking.
  • In terms of twelve month growth in earnings before interest and taxes, ALKERMES PLC is reporting a growth rate of -277.65%; that's higher than merely 4.54% of US stocks.
  • As for revenue growth, note that ALKS's revenue has grown 40.56% over the past 12 months; that beats the revenue growth of 88.8% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ALKERMES PLC are ATEN, MDRX, VNDA, AXTI, and CSGS.
  • Visit ALKS's SEC page to see the company's official filings. To visit the company's web site, go to www.alkermes.com.

ALKS Valuation Summary

  • In comparison to the median Healthcare stock, ALKS's price/sales ratio is 30.95% lower, now standing at 2.9.
  • Over the past 243 months, ALKS's price/sales ratio has gone down 29.1.

Below are key valuation metrics over time for ALKS.

Stock Date P/S P/B P/E EV/EBIT
ALKS 2023-12-29 2.9 3.4 21.6 18.2
ALKS 2023-12-28 2.9 3.4 21.7 18.3
ALKS 2023-12-27 2.9 3.5 21.8 18.5
ALKS 2023-12-26 2.9 3.4 21.7 18.3
ALKS 2023-12-22 2.9 3.4 21.7 18.4
ALKS 2023-12-21 2.9 3.4 21.4 18.1

ALKS Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 64.4%.
  • Its 4 year revenue growth rate is now at 52.95%.
  • Its 3 year cash and equivalents growth rate is now at 25.45%.
Over the past 34 months, ALKS's revenue has gone down $82,270,000.

The table below shows ALKS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,111.795 21.044 -158.267
2022-09-30 1,131.584 51.018 -129.14
2022-06-30 1,173.368 133.17 -94.154
2022-03-31 1,200.866 168.539 -61.654
2021-12-31 1,173.751 101.715 -48.169
2021-09-30 1,129.283 138.037 -91.684

ALKS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALKS has a Quality Grade of B, ranking ahead of 88.71% of graded US stocks.
  • ALKS's asset turnover comes in at 0.582 -- ranking 63rd of 680 Pharmaceutical Products stocks.
  • OTLK, AVEO, and LXRX are the stocks whose asset turnover ratios are most correlated with ALKS.

The table below shows ALKS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.582 0.835 -0.047
2021-06-30 0.576 0.836 -0.029
2021-03-31 0.556 0.835 -0.050
2020-12-31 0.557 0.828 -0.061
2020-09-30 0.641 0.845 -0.034
2020-06-30 0.646 0.844 -0.076

ALKS Price Target

For more insight on analysts targets of ALKS, see our ALKS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.50 Average Broker Recommendation 1.88 (Hold)

Alkermes plc - Ordinary Shares (ALKS) Company Bio


Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.


ALKS Latest News Stream


Event/Time News Detail
Loading, please wait...

ALKS Latest Social Stream


Loading social stream, please wait...

View Full ALKS Social Stream

Latest ALKS News From Around the Web

Below are the latest news stories about ALKERMES PLC that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

Equal Opportunity and Respect: Diversity, Inclusion and Belonging at Alkermes

Originally published in Alkermes September 2023 Corporate Responsibility Report NORTHAMPTON, MA / ACCESSWIRE / December 27, 2023 / Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive ...

Yahoo | December 27, 2023

Alkermes (ALKS) Outperforms Broader Market: What You Need to Know

Alkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.

Yahoo | December 22, 2023

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.

Yahoo | December 21, 2023

11 Most Promising Psychedelic Stocks According to Hedge Funds

In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […]

Yahoo | December 20, 2023

Corporate Governance at Alkermes

NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Board of Directors Our Board is currently comprised of eleven members, each of whom has a term expiring at ...

Yahoo | December 20, 2023

Read More 'ALKS' Stories Here

ALKS Price Returns

1-mo 15.34%
3-mo 35.44%
6-mo 15.30%
1-year 14.64%
3-year 64.35%
5-year -3.51%
YTD 16.01%
2023 6.16%
2022 12.34%
2021 16.59%
2020 -2.21%
2019 -30.87%

Continue Researching ALKS

Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:

Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!